# Atomoxetine to Treat Korean Children and Adolescents With Attention-Deficit/Hyperactivity Disorder (ADHD)

> **NCT00568685** · PHASE3 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 153 (actual)

## Conditions studied

- Attention Deficit Hyperactivity Disorder

## Interventions

- **DRUG:** Atomoxetine Hydrochloride
- **DRUG:** Atomoxetine hydrochloride
- **DRUG:** Atomoxetine hydrochloride

## Key facts

- **NCT ID:** NCT00568685
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-11
- **Primary completion:** 2008-11
- **Final completion:** 2008-11
- **Target enrollment:** 153 (ACTUAL)
- **Last updated:** 2010-01-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00568685

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00568685, "Atomoxetine to Treat Korean Children and Adolescents With Attention-Deficit/Hyperactivity Disorder (ADHD)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00568685. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*